Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Biomede)

Research summary

Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

Principal Investigator

Dr Shaun Robert Wilson

Contact us

Email: rhiannon.collins@ouh.nhs.uk

IRAS number

200571